USD0.000æéå€ååŒÂ  (ET)
44.80MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
1.210å§å€
1.220é«å€
135.77Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
0.36%売買å転ç
1.220忥çµå€
1.185å®å€
155.52K売買代é
æå€±é¡æ ªäŸ¡åçç
0.33PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-34.71%ç·è³ç£å©çç
3.95052é±é«å€
1.64åºæ¥é«æ¯ç%
-78.06MçŽå©ç
37.65Mæ ªåŒæ°
-2.29601æ ªåœããå©çïŒEPSïŒ
--ããŒã¿å€
-49.02%èªå·±è³æ¬å©çç
1.24052é±å®å€
2.88%æ¯ãå¹
100.00%ç²å©çç
44.80MæäŸ¡ç·é¡
-0.82ãªã¹ã¯ãªã¿ãŒã³
3.89%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Metagenomi Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå®å®ã§ããæé·ã®å¯èœæ§ã¯é¡èã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž164äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯7.67ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããåç€Ÿã®æ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯éå»1ãæéã§å¹³åçã§ããããã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ã¯åŒ±ãæ°Žæºã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Metagenomi Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Metagenomi Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Metagenomi Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Ionis Pharmaceuticals Inc
IONS
25
ææšî
ææš
売ã(3)
äžç«(2)
è²·ã(0)
ç§»åå¹³å
売ã(6)
äžç«(0)
è²·ã(0)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Metagenomi Incã®äŒæ¥æ
å ±î
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
äŒæ¥ã³ãŒãMGX
äŒæ¥åMetagenomi Inc
æé«çµå¶è²¬ä»»è
ãCEOãIrish (Jian)
ãŠã§ããµã€ãhttps://metagenomi.co/
æ ªäž»çµ±èšî
ãããã質å
Metagenomi IncïŒMGXïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îMetagenomi IncïŒMGXïŒã®çŸåšã®æ ªäŸ¡ã¯1.20ã§ãã
Metagenomi Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îMetagenomi Incã®ãã£ãã«ãŒã·ã³ãã«ã¯MGXã§ãã
Metagenomi Incã®52é±é«å€ã¯ãããã§ããïŒ
îMetagenomi Incã®52é±é«å€ã¯3.95ã§ãã
Metagenomi Incã®52é±å®å€ã¯ãããã§ããïŒ
îMetagenomi Incã®52é±å®å€ã¯1.24ã§ãã
Metagenomi Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îMetagenomi Incã®æäŸ¡ç·é¡ã¯44.99Mã§ãã
Metagenomi Inc (MGX) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãMetagenomi IncïŒMGXïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯7.67ã§ãã
Metagenomi Inc (MGX) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îMetagenomi IncïŒMGXïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-2.36ã§ãã